Active	Status	Sponsor type	Region	Phase	Filter
20 Active 107 Inactive 127 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lisdexamfetamine / Generic mfg.
NCT03337646: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism	Completed	4	48	Canada	Lisdexamfetamine Dimesylate, Vyvanse	JPM van Stralen Medicine Professional, Shire	Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder	03/23	03/23
NCT04727476: The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders	Active, not recruiting	N/A	413	Europe	Lisdexamfetamine	Aarhus University Hospital, Takeda	Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Hyperkinetic Disorder	08/21	05/22
AGUALIS, NCT03333668: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents	Active, not recruiting	N/A	20	Europe	Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo	King's College London, Shire	ADHD	12/22	03/25